Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

159 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Registry of Genetic Alterations of Taiwan Non-Small Cell Lung Cancer by Comprehensive Next-Generation Sequencing: A Real-World Cohort Study-Taiwan Cooperative Oncology Group T1521.
Liao BC, Chiang NJ, Chang GC, Su WC, Luo YH, Chong IW, Yang TY, Lai CL, Hsia TC, Ho CL, Lee KY, Hsiao CF, Ku FC, Fang WT, Chih-Hsin Yang J. Liao BC, et al. Among authors: chong iw. JCO Glob Oncol. 2024 Sep;10:e2400125. doi: 10.1200/GO.24.00125. Epub 2024 Sep 30. JCO Glob Oncol. 2024. PMID: 39348626 Free PMC article.
The clinical efficacy of Afatinib 30 mg daily as starting dose may not be inferior to Afatinib 40 mg daily in patients with stage IV lung Adenocarcinoma harboring exon 19 or exon 21 mutations.
Yang CJ, Tsai MJ, Hung JY, Lee MH, Tsai YM, Tsai YC, Hsu JF, Liu TC, Huang MS, Chong IW. Yang CJ, et al. Among authors: chong iw. BMC Pharmacol Toxicol. 2017 Dec 13;18(1):82. doi: 10.1186/s40360-017-0190-1. BMC Pharmacol Toxicol. 2017. PMID: 29237484 Free PMC article.
Nivolumab safety and efficacy in advanced, platinum-resistant, non-small cell lung cancer, radical radiotherapy-ineligible patients: A phase II study in Taiwan.
Chen YM, Chih-Hsin Yang J, Su WC, Chong IW, Hsia TC, Lin MC, Chang GC, Chiu CH, Ho CC, Wu SY, Hung JY, Wang CC, Yang TY, Yu CJ. Chen YM, et al. Among authors: chong iw. J Formos Med Assoc. 2020 Dec;119(12):1817-1826. doi: 10.1016/j.jfma.2020.01.004. Epub 2020 Feb 22. J Formos Med Assoc. 2020. PMID: 32094063 Free article. Clinical Trial.
Low-dose CT screening among never-smokers with or without a family history of lung cancer in Taiwan: a prospective cohort study.
Chang GC, Chiu CH, Yu CJ, Chang YC, Chang YH, Hsu KH, Wu YC, Chen CY, Hsu HH, Wu MT, Yang CT, Chong IW, Lin YC, Hsia TC, Lin MC, Su WC, Lin CB, Lee KY, Wei YF, Lan GY, Chan WP, Wang KL, Wu MH, Tsai HH, Chian CF, Lai RS, Shih JY, Wang CL, Hsu JS, Chen KC, Chen CK, Hsia JY, Peng CK, Tang EK, Hsu CL, Chou TY, Shen WC, Tsai YH, Tsai CM, Chen YM, Lee YC, Chen HY, Yu SL, Chen CJ, Wan YL, Hsiung CA, Yang PC; TALENT Investigators. Chang GC, et al. Among authors: chong iw. Lancet Respir Med. 2024 Feb;12(2):141-152. doi: 10.1016/S2213-2600(23)00338-7. Epub 2023 Nov 29. Lancet Respir Med. 2024. PMID: 38042167
Clinical outcome of bevacizumab or ramucirumab combined with epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors as the first line therapy in susceptible EGFR-mutated advanced non-small-cell lung.
Kuo CY, Tsai MJ, Hung JY, Lee MH, Wu KL, Tsai YC, Chuang CH, Huang CW, Chen CL, Yang CJ, Chong IW. Kuo CY, et al. Among authors: chong iw. Kaohsiung J Med Sci. 2024 May;40(5):467-476. doi: 10.1002/kjm2.12822. Epub 2024 Mar 25. Kaohsiung J Med Sci. 2024. PMID: 38523603 Free article.
159 results